Literature DB >> 30291346

H3K27me3 deficiency defines a subset of dedifferentiated chondrosarcomas with characteristic clinicopathological features.

Naohiro Makise1,2, Masaya Sekimizu3, Eiichi Konishi4, Toru Motoi5, Takashi Kubo6, Hisashi Ikoma7, Shun-Ichi Watanabe8, Tomotake Okuma9, Nobuyoshi Hiraoka1, Masashi Fukayama2, Akira Kawai10,11, Hitoshi Ichikawa3,6, Akihiko Yoshida12,13.   

Abstract

Dedifferentiated chondrosarcoma is a rare bone sarcoma, whose genetic background remains incompletely understood. Mutations in SUZ12 or EED, which encode polycomb repressive complex 2 (PRC2) components, and resulting deficiency in H3K27me3 are characteristic features of the majority of malignant peripheral nerve sheath tumors. Here, we investigated H3K27me3 and PRC2 status in dedifferentiated chondrosarcoma. Among 19 evaluable dedifferentiated chondrosarcoma cases, six (32%) showed immunohistochemical loss of H3K27me3 only in the dedifferentiated component, whereas the well-differentiated component retained H3K27me3. H3K27me3-deficient dedifferentiated chondrosarcoma occurred in two men and four women with a median age of 66. All of these tumors affected bones of the upper half of the body, with the ribs being preferentially involved, which represented a significantly different distribution compared to that in the 13 H3K27me3-intact dedifferentiated chondrosarcomas. H3K27me3-deficient dedifferentiated chondrosarcomas were histologically different from H3K27me3-intact dedifferentiated chondrosarcomas, as the former invariably demonstrated dedifferentiated histology with a striking similarity to classic malignant peripheral nerve sheath tumor, comprising sweeping to swirling fascicles of relatively uniform spindle cells. Heterologous rhabdomyoblastic differentiation, the focal presence of grade 3 chondrosarcoma histology, and a cartilaginous component in the metastatic sites were exclusively seen in some cases of H3K27me3-deficient dedifferentiated chondrosarcoma. In all three H3K27me3-deficient dedifferentiated chondrosarcomas that contained focal grade 3 histology, dedifferentiated components did not juxtapose to the grade 3 areas but transitioned abruptly from the grade 1-2 components. Targeted next generation sequencing, which was successfully performed on four H3K27me3-deficient dedifferentiated chondrosarcomas, identified an IDH2 mutation in one case and COL2A1 truncations in three cases. The dedifferentiated areas of three cases harbored SUZ12 or EED alterations, which were absent in the well-differentiated component, suggesting a role for PRC2 aberrations in dedifferentiation. H3K27me3 deficiency defines a novel subset of dedifferentiated chondrosarcoma that requires recognition because of its diagnostic and potential clinical implications.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30291346     DOI: 10.1038/s41379-018-0140-5

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  4 in total

Review 1.  What's new in nerve sheath tumors.

Authors:  Anders Meyer; Steven D Billings
Journal:  Virchows Arch       Date:  2019-11-09       Impact factor: 4.064

Review 2.  What is new about the molecular genetics in matrix-producing soft tissue tumors? -The contributions to pathogenetic understanding and diagnostic classification.

Authors:  Yu-Chien Kao; Jen-Chieh Lee; Hsuan-Ying Huang
Journal:  Virchows Arch       Date:  2019-11-07       Impact factor: 4.064

3.  Conventional chondrosarcoma with focal clear cell change: a clinicopathological and molecular analysis.

Authors:  Suk Wai Lam; Kirsten van Langevelde; Albert J H Suurmeijer; Arjen H G Cleven; Judith V M G Bovée
Journal:  Histopathology       Date:  2019-09-13       Impact factor: 7.778

4.  Assessment of H3K27me3 immunohistochemistry and combination of NF1 and p16 deletions by fluorescence in situ hybridization in the differential diagnosis of malignant peripheral nerve sheath tumor and its histological mimics.

Authors:  Shintaro Sugita; Tomoyuki Aoyama; Makoto Emori; Tomomi Kido; Tomoko Takenami; Kodai Sakuraba; Kotomi Terai; Taro Sugawara; Mitsuhiro Tsujiwaki; Tadashi Hasegawa
Journal:  Diagn Pathol       Date:  2021-08-30       Impact factor: 2.644

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.